Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NKTR

NKTR - Nektar Therapeutics Stock Price, Fair Value and News

$35.91-2.12 (-5.57%)
Market Closed

6/100

NKTR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

NKTR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$29.69

Target 3M

$33.4

Target 6M

$31.54

NKTR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NKTR Price Action

Last 7 days

-2.7%

Last 30 days

-16.0%

Last 90 days

-42.8%

Trailing 12 Months

185%

NKTR RSI Chart

NKTR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NKTR Valuation

Market Cap

730.5M

Price/Earnings (Trailing)

-6.06

Price/Sales (Trailing)

11.67

EV/EBITDA

-6.12

Price/Free Cashflow

-3.84

NKTR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$29.69

Target 3M

$33.4

Target 6M

$31.54

NKTR Fundamentals

NKTR Revenue

Revenue (TTM)

62.6M

Rev. Growth (Yr)

-51.13%

Rev. Growth (Qtr)

5.5%

NKTR Earnings

Earnings (TTM)

-120.5M

Earnings Growth (Yr)

4.14%

Earnings Growth (Qtr)

14.7%

NKTR Profitability

EBT Margin

-181.76%

Return on Equity

-141.65%

Return on Assets

-40%

Free Cashflow Yield

-26.06%

NKTR Investor Care

Shares Dilution (1Y)

65.42%

Diluted EPS (TTM)

-7.85

NKTR Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202587.2M74.9M62.6M0
202490.2M93.2M93.1M98.4M
202388.8M87.7M88.3M90.1M
2022103.1M96.3M95.0M92.1M
2021126.0M105.5M100.4M101.9M
2020137.0M162.5M163.3M152.9M
20191.2B119.1M120.6M114.6M
2018529.1M750.5M971.9M1.2B
2017131.3M133.1M249.7M307.7M
2016180.9M191.0M167.4M165.4M
2015289.7M283.9M211.0M230.8M
2014145.7M140.3M212.3M200.7M
201386.2M96.4M138.9M148.9M
201278.1M84.5M75.8M81.2M
2011137.1M111.9M101.0M71.5M
2010000159.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Nektar Therapeutics

NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
 CEO
 WEBSITEnektar.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES216

Nektar Therapeutics Frequently Asked Questions

NKTR is the stock ticker symbol of Nektar Therapeutics. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Nektar Therapeutics is 730.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NKTR's fair value in chart for subscribers.

The fair value guage provides a quick view whether NKTR is over valued or under valued. Whether Nektar Therapeutics is cheap or expensive depends on the assumptions which impact Nektar Therapeutics's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTR.

As of Wed Jan 28 2026, NKTR's PE ratio (Price to Earnings) is -6.06 and Price to Sales (PS) ratio is 11.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Nektar Therapeutics has provided -0.16 (multiply by 100 for percentage) rate of return.